🇺🇸 From Cleveland, Ohio, to the nation, Happy 4th of July. At Abeona Therapeutics, we're advancing cutting-edge gene and cell therapy to help those living with recessive dystrophic epidermolysis bullosa. This Independence Day, we celebrate the innovation and determination that drive us toward a brighter future for all. #IndependenceDay #cellandgenetherapy #RareDiseases #Innovation #AbeonaTherapeutics #RDEB #WeFightEB #PatrioticScience
Abeona Therapeutics’ Post
More Relevant Posts
-
Introducing our stellar lineup of speakers for the BioCon Asia-ACGT Conference, featuring trailblazers in gene and cell therapy. These experts are shaping the future of healthcare and making waves in their respective fields. Don't miss the chance to learn from the best! 🌟🧬 Act fast and grab your early bird and group tickets now for a limited time! Scan the QR code for more details and to secure your spot at this groundbreaking event. 🚀🎟️ #BioConAsiaACGT #GeneTherapy #CellTherapy #HealthcareInnovation #BioConAsiaACGT #GeneTherapy #CellTherapy #HealthcareInnovation
-
-
Meet with Ion Tcacencu, MD/PhD. and Annemiek Stijnen at this exciting event to discuss how Venn Life Sciences can support you!!!
We are heading to #London to attend the Terrapinn Advanced Therapies event! 📅 19-20 March 2024 📍 Double Tree Excel, London The Advanced Therapies Congress features speakers from across the entire value chain of cell and gene therapy development; forward-thinking pharma, biotech and startup companies, researchers, clinicians, academics, HTAs, payers, regulators. Meet with our #Venn colleagues Ion Tcacencu, MD/PhD. and Annemiek Stijnen at this exciting event to discuss how Venn Life Sciences can support you. #Conference #ATMP #CMC #Consultants
-
Looking forward to seeing everyone in London soon! Check out our presentation on day 2: “Bespoke discovery of novel human promoters for improved safety and efficacy in gene and cell therapy”
We will be attending Advanced Therapies 19and 20 March in London. Founder and CEO Joris van Arensbergen will be presenting on 20 March at 2.40pm: “Bespoke discovery of novel human promoters for improved safety and efficacy in gene and cell therapy”. You can find us at booth S51 as well or reach out through the networking app for a meeting during which we can tell you all about improving efficacy and safety of your therapy with our SuRE™ promoters and AIM™ integration site mapping. #adtherapies24 #humanpromoters #cellandgenetherapy #cellengineering
-
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)
-
Attending the 30th Annual European Society of Gene and Cell Therapy Congress in Brussels this week? Learn about how the Kytopen team has optimized transfection with #Flowfect® for natural killer cells and RNP! Stop by the poster sessions to see Gretchen Lewis Wednesday and Thursday evenings and learn more. #cellandgenetherapy #celltherapymanufacturing #esgct #nonviral
-
-
Authentic senior business leader with a track record in cross-functional decision making. Driving disruptive transformational programs in a people centric way. Building bridges between internal & external stakeholders.
#Gene and #cell-based therapies have the potential to provide targeted and personalized treatments, according to Charité - Universitätsmedizin Berlin and Bayer. They are a beacon of hope for people for whom conventional therapies have failed or for whom there is no treatment so far. With Charité and Bayer, two partners for major medical progress are coming together who will establish a new center for gene and cell therapy in #Berlin, which is to be established in 2025. More information in first comment #healthforall #teambayer
-
-
Don’t forget to attend our sponsored session at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting on Friday, May 10 from 8-8:30 a.m. EDT. This session will cover how strategic collaborations between #CDMOs and #CROs are addressing industry challenges related to #viralvector production, leading to: - Improved AAV production titer with a significant reduction in cost of goods via high-throughput processes and analytical development - Direct scale-up from bench to 2,000L - Strategies for enhancing % full enrichment during downstream processing - Developing customer-centric analytics for viral vector characterization in development and GMP settings Learn more about this sponsored session here: http://spr.ly/6047jdT23
Session Details | Revolutionizing gene therapy services | ASGCT Annual Meeting
